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Abstract: Inflammation is a complex mechanism of cell/tissue responses to injuries triggered by multiple causes, including
trauma, pathogens or autoimmune abnormal responses. In the last years, a novel line of thought is emerging by giving a more
holistic vision of chronic arthropathies through a recently identified group of molecules, called adipokines. Actually, most of
these recently identified factors, produced prevalently by white adipose tissue but also by cells of the joints (chondrocytes and
synovial fibroblasts) and immune cells, play a significant role in chronic inflammation. Adipokines dysregulation has emerged as
a common characteristic of chronic inflammation in rheumatic diseases in particular when obesity or, more precisely, adipose tis-
sue dysfunction is associated with common rheumatic diseases, such as osteoarthritis and rheumatoid arthritis. In this MiniRe-
view, we discuss the role of adipokines in osteoarthritis and rheumatoid arthritis providing an updated overview of their
pathophysiological role and potential use as therapeutic targets.
With the discovery of leptin in 1994 [1], white adipose tissue
(WAT) has been recognized to be a true endocrine organ, which
is able to secrete a wide variety of factors termed adipokines
[2,3]. In spite of their metabolic activities, adipokines represent
a new family of compounds that could participate in several
processes, including inflammation and immunity [4–6], and are
also involved in the pathophysiology of rheumatic diseases.
Adipokines include a variety of pro-inflammatory factors
most of them being increased in obesity and appearing to con-
tribute to the so-called ‘low-grade inflammatory state’ in obese
individuals.
Obesity, the condition that spurred the research on adipokin-
es, has been considered a risk factor for developing osteoar-
thritis (OA) [7,8]. It has been reported that obesity increases
the incidence of OA, particularly in weight-bearing joints such
as knees [9], but the fact that obese individuals have an
increased risk of OA also in non-weight-bearing joints such as
hands, wrists and shoulder [10,11], which reveals that soluble
factors, adipokines indeed, are at play in the onset and pro-
gression of this rheumatic disease.
The aim of this MiniReview is to present the data concerning
the role of two important adipokines: leptin and adiponectin.
We analyse the role of these adipokines in inflammation focus-
ing our attention on their involvement in rheumatic diseases,
particularly in osteoarthritis (OA) and rheumatoid arthritis (RA).
Leptin
Leptin, the protein product of the ob gene, the murine homo-
logue of human LEP gene [1] exerts its biological actions
through the activation of its OB-Rb long-form receptor iso-
form that is encoded by the gene diabetes (db) and belongs to
the class 1 cytokine receptor superfamily. This hormone
decreases food intake increasing anorexigenic factors as
cocaine- and amphetamine-related transcript (CART) and
increases energy consumption by suppressing orexigenic neu-
ropeptides such as neuropeptide Y (NPY) [12]. Leptin levels
are mostly dependent on the amount of body fat, but its syn-
thesis is also regulated by inflammatory mediators [13].
Leptin and Rheumatic Diseases
It is increasingly evident that this hormone plays a key role in the
rheumatic diseases, particularly osteoarthritis (OA) and rheuma-
toid arthritis (RA). Serum leptin levels are increased in patients
with OA [14], and although some initial findings have suggested
an anabolic role of this hormone in the cartilage [15], most stud-
ies reveal a catabolic role of leptin at cartilage level. For instance,
our group has demonstrated that, in cultured human and murine
chondrocytes, type 2 nitric oxide synthase (NOS2) is synergisti-
cally activated by the combination of leptin plus interferon-c or
IL-1b via a mechanism involving JAK2, PI3K and mitogen-acti-
vated kinases (MEK1 and p38) [4,16]. Nitric oxide (NO), which
is induced by a wide range of pro-inflammatory cytokines, is a
well-known pro-inflammatory mediator on joint cartilage, where
it triggers chondrocyte phenotype loss, apoptosis and metallopro-
teinases (MMPs) activatiozn.
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Recently, it has been demonstrated that leptin is able to
induce also the expression of MMPs involved in OA cartilage
damage, such as MMP-9 and MMP-13 [17]. In fact, condi-
tioned media from osteoarthritic infrapatellar fat pad, contain-
ing leptin, induce the synthesis of certain MMPs [18],
demonstrating that the local production of leptin participate in
the degradation processes occurred in the joints. More evi-
dence suggested that leptin, alone and in combination with IL-
1b, up-regulates MMP-1 and MMP-3 production in human
OA cartilage through the transcription factor NF-jB, protein
kinase C and MAP kinase pathways. This adipokine is also
correlated positively with MMP-1 and MMP-3 in synovial
fluid from patients with OA [19]. Noteworthy, very recently,
leptin has been demonstrated to increase IL-8 production in
human chondrocytes [20]. Additionally, the gene expression
of ADAMTS-4 and ADAMTS-5 was markedly increased, and
a depletion of proteoglycan in articular cartilage was observed
after treatment with leptin [21].
Very recently, our group demonstrated that leptin is also
able to increase the expression of vascular cell adhesion mole-
cule-1 (VCAM-1), a relevant adhesion molecule involved in
the recruitment and extravasation of leucocytes from circulat-
ing blood to inflamed joints [22].
Leptin and leptin’s receptor expression levels were signifi-
cantly increased in advanced OA cartilage and in synovial fluid
[23]. Moreover, a very recent study showed that leptin bioactive
levels are increased in synovial fluid from obese patients with
OA, and SOCS-3 (a typically leptin-induced signalling suppres-
sor) expression in cartilage is decreased in these patients com-
pared with non-obese patients with OA [23].
These results suggested that leptin might act as a pro-
inflammatory factor on cartilage metabolism, suggesting a
prominent catabolic effect in OA joints.
Leptin was also implicated in autoimmune diseases such as
RA, but the role of this adipokine in this disease is still
unclear. In patients with RA, circulating leptin levels have
been described as either higher or unmodified in comparison
with healthy controls [17,24]. Experimental antigen-induced
arthritis is less severe in leptin-deficient ob/ob mice than in
wild-type mice, whereas leptin-deficient mice and leptin-recep-
tor-deficient mice exhibited a delayed resolution of the inflam-
matory process in zymosan-induced experimental arthritis.
Notably, leptin decreased the severity of septic arthritis in
wild-type mice. So, in the light of the present results, it seems
difficult to make an unambiguous conclusion about a potential
role of leptin in RA [25]. Several studies have also demon-
strated that there may exist a close dependence between the
risk of aggressive course of RA and leptin levels [26,27]. In
addition, a correlation between serum leptin, synovial fluid/
serum leptin ratio, disease duration and parameters of RA
activity has been also reported [28].
It is relevant to mention that current biological treatments
for RA, such as anti-TNF (tumour necrosis factor) therapies,
do not directly modulate leptin levels [29–31].
Many studies have demonstrated the effect of this adipokine
in different joint cell types. Apart from the prominent activity
of leptin in chondrocytes, which was shown by our group and
others [4,16,22,32], leptin has more recently been shown to
exert a pro-inflammatory effect in synovial fibroblasts. Leptin
induced IL-8 production in these cells via a mechanism
involving a canonical activation of the leptin receptor and
nuclear factor jB (NFjB) [33]. To note, this effect was also
demonstrated by our group in human chondrocytes [20].
The action of leptin in RA is not only targeted to articu-
lar tissue; this adipokine also exerts direct modulatory
effects on activation, proliferation, maturation and production
of inflammatory mediators in a variety of immune cells
[34].
In particular, it is known that leptin is able to modulate T
regulatory cells (Treg) that are potent suppressors of autoim-
munity. Matarese et al. have recently demonstrated that leptin
secreted by adipocytes sustains Th1 immunity by promoting
effector T cell proliferation and by constraining Treg cells
expansion [35]. Weight loss, with concomitant reduction in
leptin levels, induces a reduction in effector T cells prolifera-
tion and an increased expansion of Treg cells leading to a
down-regulation of Th1 immunity and cell-mediated autoim-
mune diseases associated with increased susceptibility to infec-
tions. On the contrary, an increase in adipocyte mass leads to
high leptin secretion, which results in expansion of effector T
cells and reduction in Treg cells. This fact determines an over-
all enhancement of the pro-inflammatory immunity and of T
cell-mediated autoimmune disorders.
Very recently, it has been demonstrated that leptin can acti-
vate mammalian target of rapamycin (mTOR) and regulate the
proliferative capacity of regulatory T cells. This study suggests
that the leptin-mTOR signalling pathway is an important link
between host energy status and Treg cell activity. Authors
conclude that oscillating mTOR activity is necessary for Treg
cell activation and suggest that this might explain why Treg
cells are unresponsive to TCR stimulation in vitro when high
levels of leptin and nutrients may sustain mTOR activation
[35,36]. However, leptin can be considered as a link among
immune tolerance, metabolic function and autoimmunity, and
future strategies aimed at interfering with leptin signalling
may represent innovative therapeutic tools for autoimmune
disorders.
Adiponectin
Adiponectin, also known as GBP28, apM1, Acrp30 or Adi-
poQ, is a 244-residue protein produced mainly by WAT. This
hormone has structural homology with collagens VIII and X
and complement factor C1q, and it circulates in the blood in
relatively large amounts in different molecular forms [37,38].
It increases fatty acid oxidation and reduces the synthesis of
glucose in the liver.
Adiponectin acts via two receptors, one (AdipoR1) found
predominantly in skeletal muscle and the other (AdipoR2) in
liver. Transduction of the adiponectin signal by AdipoR1 and
AdipoR2 involves the activation of AMPK, PPAR-a, PPAR-c
and other signalling molecules [37].
© 2013 Nordic Pharmacological Society. Published by John Wiley & Sons Ltd
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Adiponectin and Rheumatic Diseases
Adiponectin has a wide range of effects in pathologies with
inflammatory component, such as cardiovascular disease,
endothelial dysfunction, type 2 diabetes, metabolic syndrome
and rheumatic diseases [39]. In contrast to its previously
described protective role in vascular diseases, there are some
evidence that show that adiponectin might act as a pro-inflam-
matory factor in joints, and it could be involved in matrix deg-
radation.
Adiponectin in chondrocytes leads to the induction of
NOS2 via a signalling pathway that involves PI3 kinase. Simi-
larly, this adipokine increases IL-6, MMP-3, MMP-9 and
MCP-1 production in the same cell type [40]. Kang et al.
have reported that collagenase-cleaved type II collagen
neoepitope, a product of collagen type II degradation, was
increased in supernatants of adiponectin-treated OA cartilage
explants [41]. Furthermore, it has been reported that adiponec-
tin is able to induce the expression of IL-6 in human synovial
fibroblasts [42].
Adiponectin, in a similar manner to that of leptin, was
recently described as a potent inductor of VCAM-1 in chon-
drocytes, even more powerful than the classic pro-inflamma-
tory cytokine IL-1b [22]. So, it is reasonable to describe a
scenario in which this adipokine is able to perpetuate carti-
lage-degrading processes by inducing molecules responsible of
monocyte and leucocyte infiltration to the joint.
The implication of adiponectin in OA pathogenesis is sup-
ported also by clinical observations. It has been reported that
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Fig. 2. Schematic representation of the main activities of adiponectin in inflammatory response and interactions with the immune system.
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with OA than in healthy controls [43], and this adipokine has
been detected in OA synovial fluids correlating with aggrecan
degradation [44].
Actually, Filkova et al. found higher adiponectin serum lev-
els in patients with erosive OA compared with patients with
non-erosive OA [45]. In the same way, Koskinen and col-
leagues reported that serum adiponectin and adiponectin syn-
thesis from OA cartilage are higher in patients with the
radiologically most severe disease [46]. Furthermore, these
authors and others observed an association between adiponec-
tin serum levels, OA biomarkers and local synovial inflamma-
tion [14,46]. Intriguingly, adiponectin/leptin ratio was
proposed as predictor of pain in patients with OA [47]. An
increase in IL-6 and adiponectin production in the infrapatellar
fat pad (IFP) of osteoarthritic knees has been observed [48–
50]. This suggests that IFP might contribute to the local pro-
duction of cytokines and adipokines. Taken together, these
results suggest that adiponectin may be considered a potential
molecule involved in joint disorders and matrix degradation.
The potential role of adiponectin has also been actively
investigated in rheumatoid arthritis. Generally, low adiponectin
levels have been associated with obesity, type 2-diabetes, ath-
erosclerosis and vessel inflammation. So, in metabolic syn-
drome, the role of adiponectin is clearly anti-inflammatory.
On the other side, multiple studies described high adiponectin
levels in patients with RA, and these levels correlate with
severity of RA [24,51,52]. Several authors identified an asso-
ciation between serum adiponectin levels and radiographic
damage in patients with RA [48,53], suggesting that this
adipokine may be a mediator of the paradoxical relationship
between increasing adiposity and protection from radiographic
damage in RA, due to adiponectin circulating levels decrease
as adiposity increases and considering that adiponectin may
have negative effects on joints. In addition, other studies
reveal that adiponectin is also related to erosive joint destruc-
tion in RA [54], and recently, it has been described that this
adipokine is associated with the pro-inflammatory cytokine
IL-6 [55,56].
In contrast to its ‘protective’ role against obesity and vascular
diseases at joint levels, adiponectin might be pro-inflammatory.
In synovial fibroblasts, adiponectin induces IL-6 production and
MMP-1 via a p38 MAPK pathway [57]. Similarly, IL-8 is
induced by adiponectin through an intracellular pathway involv-
ing NF-jB [20,58]. In addition, adiponectin, in association with
IL-1b, synergizes in the induction of IL-6, IL-8 and prostaglan-
din E2 (PGE2) in RA synovial cells [26], suggesting that adipo-
nectin and IL-1b may act synergistically in the induction of
pro-inflammatory factors during RA progression.
Recent studies showed that adiponectin might also contrib-
ute to synovitis and joint destruction in RA by stimulating
MMP-1, MMP-13 and vascular endothelial growth factor
(VEGF) expression in synovial cells, surprisingly, more than
conventional pro-inflammatory mediators (i.e. IL-1b) [59]. A
recent study performed in RA synovial fibroblasts (RASFs)
showed that adiponectin increases both cyclooxygenase-2
(COX-2) and membrane-associated PGE synthase-1 (mPGES-
1) mRNA and protein expression, resulting in an increase in
PGE2 production in a time- and concentration-dependent man-
ner [60]. This increase was inhibited by siRNA against adipo-
nectin receptor (AdipoR1 and AdipoR2) or using inhibitors of
specific proteins involved in adiponectin signal transduction
[60]. Frommer et al. have confirmed the pro-inflammatory
role of adiponectin in RA by demonstrating that this adipokine
promotes inflammation through cytokine synthesis by the dif-
ferent cells present in the joint. Also, it participates in the
attraction of inflammatory cells to the synovium via chemo-
kines synthesis and promoting matrix destruction due to the
increased release of matrix metalloproteinases by chondrocytes
[61]. Moreover, these authors described that the different iso-
forms of adiponectin can induce the expression of different
genes involved in the pathogenesis of RA [62], supporting the
concept that adiponectin has detrimental effects in joint
inflammatory diseases like RA.
Conclusions
Several clinical and experimental lines of evidence showed
that adipokines could contribute to inflammatory/immune and
rheumatic diseases (Figs 1 and 2). The relationship between
obesity and rheumatic diseases, such as OA, has been consid-
ered a mere stress for decades. However, the discovery of
these adipose-derived factors introduced a novel idea of a
close metabolic relationship. The recent knowledge about
adipokines activities in rheumatic and inflammatory diseases
opens up new potential therapeutic strategies. For instance, the
use of specific antibodies in a similar way to anti-TNF-a ther-
apy might be an interesting approach. Also, some data suggest
that adipokines might serve as biomarkers of the severity of
certain rheumatic diseases.
However, only further insights into the deep mechanisms by
which adipokines are regulated, and the elucidation of the
potential role of adipokines in the pathogenesis of rheumatic
diseases might propose new pharmacological approaches.
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